Not Signed In -
Insulin aspart |
Humalog Aspart; Humulin Aspart; insulin aspart [rDNA origin]; Novolin Aspart; NovoLog |
Clinical Trial: Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Pediatric Population
This study has been completed.
|
Purpose
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diabetes Mellitus, Insulin-Dependent | Drug: Insulin Aspart (NovoLog®) Drug: Regular Human Insulin (Novolin®R) Drug: Insulin Lispro (Humalog®) in combination with NPH | Phase III |
MedlinePlus related topics: Juvenile Diabetes
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Bio-equivalence Study
Further Study Details:
Expected Total Enrollment: 300
Study start: June 2002; Study completion: November 2003
Eligibility
Ages Eligible for Study: 6 Years - 18 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
- Pediatric patients with Type 1 diabetes for at least one year
- HbA1c < 12%
- Willing to administer at least 3 injections per day,
- Willing to perform SMBG at least 4 times per day, includes subject and/or parent/guardian, as necessary
Location Information
New Jersey
Novo Nordisk Call Center, Princeton, New Jersey, 08540, United States
More Information
Study ID Numbers: ANA-2126
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: October 23, 2003
ClinicalTrials.gov Identifier: NCT00071448
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: October 23, 2003
ClinicalTrials.gov Identifier: NCT00071448
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
